[1] Kwon-Chung KJ, Fraser JA, Doering TL, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med, 2014; 4, a019760.
[2] Casalini G, Giacomelli A, Antinori S. The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation. Lancet Microbe, 2024; 5, 717−24. doi:  10.1016/S2666-5247(24)00042-9
[3] Chinese Thoracic Society. Clinical practice guidelines for the diagnosis and management of invasive pulmonary fungal diseases (2025 edition). Chin J Tuberc Respir Dis, 2025; 48, 1104−26. (In Chinese)
[4] Chen MY, Chen SY, Wang M, et al. A multicenter prospective clinical cohort study of pulmonary cryptococcosis in adult non-HIV-infected patients in a southeastern province of China. Respir Res, 2025; 26, 216. doi:  10.1186/s12931-025-03283-w
[5] Fang W, Fa ZZ, Liao WQ. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet Biol, 2015; 78, 7−15. doi:  10.1016/j.fgb.2014.10.017
[6] Zhejiang Medical Association Society of Respiratory Diseases. Expert consensus on diagnosis and treatment of pulmonary cryptococcosis. Chin J Clin Infect Dis, 2017; 10, 321−6. (In Chinese)
[7] Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc, 2013; 124, 61−79.
[8] Fang WJ, Chen M, Liu J, et al. Cryptococcal meningitis in systemic lupus erythematosus patients: pooled analysis and systematic review. Emerg Microbes Infect, 2016; 5, 1−7.
[9] Qu JY, Zhang XL, Lu Y, et al. Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China. Sci Rep, 2020; 10, 9387. doi:  10.1038/s41598-020-66094-7
[10] Wang Y, Gu Y, Shen KL, et al. Clinical features of cryptococcosis in patients with different immune statuses: a multicenter study in Jiangsu Province-China. BMC Infect Dis, 2021; 21, 1043. doi:  10.1186/s12879-021-06752-x
[11] Ponzio V, Chen Y, Rodrigues AM, et al. Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. Emerg Microbes Infect, 2019; 8, 119−29. doi:  10.1080/22221751.2018.1562849
[12] Onishi T, Sada KE, Hayashi K, et al. Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA). Arthritis Res Ther, 2024; 26, 198. doi:  10.1186/s13075-024-03434-2
[13] Rajasingham R, Govender NP, Jordan A, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis, 2022; 22, 1748−55. doi:  10.1016/S1473-3099(22)00499-6
[14] National Clinical Research Center for Infectious Diseases, The Infectious Diseases Branch of the Medical Association of Western Returned Scholars Association (Overseas-educated Scholars Association of China), The Microecology Medicine Branch of Guangdong Medical Association. Chinese guideline on the diagnosis and treatment of invasive fungal diseases in people living with human immunodeficiency virus/acquired immune deficiency syndrome (edition update). Chin J Infect Dis, 2024; 42, 513−29. (In Chinese)
[15] Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis, 2001; 7, 375−81. doi:  10.3201/eid0703.017302
[16] Kim DY, Oh K, Song M, et al. Epidemiology and characteristics of invasive yeast infections in patients with hematologic diseases: 12-year single-center retrospective cohort study. J Fungi, 2025; 11, 585. doi:  10.3390/jof11080585
[17] Gold JAW, Benedict K, Sajewski E, et al. Invasive fungal disease in solid organ and hematopoietic cell transplant recipients, United States. Transpl Infect Dis, 2025; 27, e70077. doi:  10.1111/tid.70077
[18] Zhu LP, Wu JQ, Xu B, et al. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med Mycol, 2010; 48, 570−9. doi:  10.3109/13693780903437876
[19] Wang Y, Gu Y, Shen KL, et al. The management and outcome of cryptococcosis in patients with different immune statuses and treatment protocols: a multicenter real-world study in Jiangsu Province - China. J Mycol Med, 2023; 33, 101389. doi:  10.1016/j.mycmed.2023.101389
[20] Temfack E, Bigna JJ, Luma HN, et al. Impact of routine cryptococcal antigen screening and targeted preemptive fluconazole therapy in antiretroviral-naive human immunodeficiency virus-infected adults with CD4 Cell Counts <100/μL: a systematic review and meta-analysis. Clin Infect Dis, 2019; 68, 688−98. doi:  10.1093/cid/ciy567
[21] Awotiwon AA, Johnson S, Rutherford GW, et al. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. Cochrane Database Syst Rev, 2018; 8, CD004773.
[22] Li Y, Huang XJ, Chen H, et al. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis. BMC Infect Dis, 2020; 20, 410. doi:  10.1186/s12879-020-05126-z
[23] Ford N, Shubber Z, Jarvis JN, et al. CD4 Cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis, 2018; 66, S152−9. doi:  10.1093/cid/cix1143
[24] Lourens A, Jarvis JN, Meintjes G, et al. Rapid diagnosis of cryptococcal meningitis by use of lateral flow assay on cerebrospinal fluid samples: influence of the high-dose “hook” effect. J Clin Microbiol, 2014; 52, 4172−5. doi:  10.1128/JCM.01683-14
[25] Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis, 2014; 20, 45−53. doi:  10.3201/eid2001.130906
[26] Wang SG, Chen X, Shi JS, et al. Evaluation of cryptococcal antigen lateral flow assay in human immunodeficiency virus-negative cryptococcosis: a diagnostic accuracy study. Clin Microbiol Infect, 2025; 31, 1720−5. doi:  10.1016/j.cmi.2025.06.021
[27] Tang ZY, Xu P, Wang ZH, et al. Evaluation of cryptococcal antigen testing using a novel chemiluminescence assay in two medical centers of China. Front Cell Infect Microbiol, 2024; 14, 1451539. doi:  10.3389/fcimb.2024.1451539
[28] Dai CM, Bai DY, Lin CB, et al. The relationship between lung CT features and serum cryptococcal antigen titers in localized pulmonary cryptococcosis patients. BMC Pulm Med, 2024; 24, 441. doi:  10.1186/s12890-024-03259-4
[29] Bennett JE, Williamson PR. Antigen titers in cryptococcal meningitis: what determines how fast they fall?. J Infect Dis, 2024; 230, 1291−6. doi:  10.1093/infdis/jiae354
[30] Shi JJ, Chen JH, Ding QJ, et al. Lateral flow assay as radiological prognosis factor of pulmonary cryptococcosis: a single center retrospective study in China. Front Cell Infect Microbiol, 2025; 14, 1497082. doi:  10.3389/fcimb.2024.1497082
[31] Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis, 2008; 47, 674−83. doi:  10.1086/590566
[32] Temfack E, Rim JJB, Spijker R, et al. Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults living with human immunodeficiency virus: systematic review and meta-analysis of diagnostic test accuracy studies. Clin Infect Dis, 2021; 72, 1268−78. doi:  10.1093/cid/ciaa1243
[33] Chen M, Zhou J, Li J, et al. Evaluation of five conventional and molecular approaches for diagnosis of cryptococcal meningitis in non-HIV-infected patients. Mycoses, 2016; 59, 494−502. doi:  10.1111/myc.12497
[34] Jiang ZJ, Hong JC, Lin BW, et al. Comparison of mNGS with conventional methods for diagnosis of cryptococcal meningitis: a retrospective study. Sci Rep, 2025; 15, 3656. doi:  10.1038/s41598-025-86481-2
[35] Walukaga S, Fieberg A, Musubire A, et al. The evolution of HIV-associated cryptococcal meningitis in Uganda from 2010 to 2022. Med Mycol, 2025; 63, myae115. doi:  10.1093/mmy/myaf115
[36] Chen LA, She DY, Liang ZX, et al. A prospective multi-center clinical investigation of HIV-negative pulmonary cryptococcosis in China. Chin J Tuberc Respir Dis, 2021; 44, 14−27. (In Chinese)
[37] Yin YY, Zhu PY, Guo YF, et al. Enhancing lower respiratory tract infection diagnosis: implementation and clinical assessment of multiplex PCR-based and hybrid capture-based targeted next-generation sequencing. eBioMedicine, 2024; 107, 105307. doi:  10.1016/j.ebiom.2024.105307
[38] Ding YC, Jing CW, Wei JC, et al. Comparison of the diagnostic capabilities of tNGS and mNGS for pathogens causing lower respiratory tract infections: a prospective observational study. Front Cell Infect Microbiol, 2025; 15, 1578939. doi:  10.3389/fcimb.2025.1578939
[39] Society of Clinical Microbiology of China International Exchange and Promotion Association for Medical and Healthcare. Expert consensus on the application and practice of targeted next-generation sequencing in infectious diseases. Natl Med J China, 2024; 104, 4375−83. (In Chinese)
[40] Xing XW, Zhang JT, Ma YB, et al. Metagenomic next-generation sequencing for diagnosis of infectious encephalitis and meningitis: a large, prospective case series of 213 patients. Front Cell Infect Microbiol, 2020; 10, 88. doi:  10.3389/fcimb.2020.00088
[41] Zhang LY, Wang SS, Hong N, et al. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans species complex from China, including the diploid VNIII isolates from HIV-infected patients in Chongqing region. Med Mycol, 2023; 61, myad119. doi:  10.1093/mmy/myad119
[42] Xiao M, Chen SCA, Kong FR, et al. Five-year China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study of invasive fungal infections caused by noncandidal yeasts: species distribution and azole susceptibility. Infect Drug Resist, 2018; 11, 1659−67. doi:  10.2147/IDR.S173805
[43] Al-Odaini N, Li XY, Li BK, et al. In vitro antifungal susceptibility profiles of Cryptococcus neoformans var. grubii and Cryptococcus gattii clinical isolates in Guangxi, Southern China. Front Microbiol, 2021; 12, 708280. doi:  10.3389/fmicb.2021.708280
[44] Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis, 2024; 24, e495−512. doi:  10.1016/S1473-3099(23)00731-4
[45] Leslie KO, Wick MR. Practical pulmonary pathology: a diagnostic approach. 3rd ed. Elsevier. 2018, 184-6.
[46] Roden AC, Schuetz AN. Histopathology of fungal diseases of the lung. Semin Diagn Pathol, 2017; 34, 530−49. doi:  10.1053/j.semdp.2017.06.002
[47] Ristow LC, Davis JM. The granuloma in cryptococcal disease. PLoS Pathog, 2021; 17, e1009342. doi:  10.1371/journal.ppat.1009342
[48] Goldblum JR, Lamps LW, McKenney JK. Rosai and Ackerman’s surgical pathology. 11th ed. Elsevier. 2018, 1969-70.
[49] Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet, 2014; 53, 429−54. doi:  10.1007/s40262-014-0139-0
[50] Expert Panel for Clinical Rational Application of Amphotericin B Deoxycholate, Infectious Diseases Society of China, Chinese Society of Bacterial Infection and Resistance. Expert consensus on rational clinical application of amphotericin B deoxycholate (2022). Natl Med J China, 2023; 103, 1173−83. (In Chinese)
[51] Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection, 2017; 45, 737−79. doi:  10.1007/s15010-017-1042-z
[52] Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev, 1999; 12, 501−17. doi:  10.1128/CMR.12.4.501
[53] Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother, 2000; 46, 171−9.
[54] Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis, 2012; 54, 121−8. doi:  10.1093/cid/cir745
[55] Yao Y, Zhang JT, Yan B, et al. Voriconazole: a novel treatment option for cryptococcal meningitis. Infect Dis, 2015; 47, 694−700. doi:  10.3109/23744235.2015.1044260
[56] Fernández Plaza J, Gregorio Malagón S, Poyato Borrego M, et al. Use of isavuconazole in cryptococcal meningitis in a cirrhotic patient. Enferm infecc Microbiol Clin, 2024; 42, 460−2. doi:  10.1016/j.eimc.2024.04.008
[57] Flores VG, Tovar RMC, Zaldivar PG, et al. Meningitis due to Cryptococcus neoformans: treatment with posaconazole. Curr HIV Res, 2012; 10, 620−3.
[58] Yang M, Cheng L, Dai Q, et al. A novel cryptococcal meningitis therapy: the combination of amphotericin B and posaconazole promotes the distribution of amphotericin B in the brain tissue. BioMed Res Int, 2020; 2020, 8878158. doi:  10.1155/2020/8878158
[59] Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother, 2014; 69, 1162−76. doi:  10.1093/jac/dkt508
[60] Nocua-Báez LC, Uribe-Jerez P, Tarazona-Guaranga L, et al. Azoles of then and now: a review. Rev Chil Infectol, 2020; 37, 219−30.
[61] Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations—A systematic review and meta-analysis. Mycoses, 2017; 60, 146−54. doi:  10.1111/myc.12585
[62] Branch of Organ Transplantation, Chinese Medical Association. Guideline for the clinical diagnosis and treatment of cryptococcosis in kidney transplant recipients. Chin J Organ Transplant, 2025; 46, 334−43. (In Chinese)
[63] Li F, Yu XX, Li M, et al. Cryptococcal infection: host immunity, immune evasion and emerging immunotherapeutic strategies. Front Cell Infect Microbiol, 2025; 15, 1671873. doi:  10.3389/fcimb.2025.1671873
[64] Li X, Paccoud O, Chan KH, et al. Cryptococcosis associated with biologic therapy: a narrative review. Open Forum Infect Dis, 2024; 11, ofae316. doi:  10.1093/ofid/ofae316
[65] Prevel R, Guillotin V, Imbert S, et al. Central nervous system cryptococcosis in patients with sarcoidosis: comparison with non-sarcoidosis patients and review of potential pathophysiological mechanisms. Front Med, 2022; 9, 836886. doi:  10.3389/fmed.2022.836886
[66] Huang HR, Fan LC, Rajbanshi B, et al. Lumbar puncture for non-HIV-infected non-transplant patients with cryptococcosis: Should it be mandatory for all? PLoS One, 2019; 14, e0221657.
[67] Miwa T, Okamoto K, Ikeuchi K, et al. The role of frequent screening or diagnostic testing of serum cryptococcal antigen in liver transplant recipients: a descriptive epidemiology. Open Forum Infect Dis, 2024; 11, ofae255. doi:  10.1093/ofid/ofae255
[68] Yuan D, Li K, Zheng XY, et al. Effectiveness of voriconazole therapy for pulmonary cryptococcosis in fluconazole treatment failure: a multicenter real-world study. BMC Infect Dis, 2025; 25, 1609. doi:  10.1186/s12879-025-11985-1
[69] Tien RD, Chu PK, Hesselink JR, et al. Intracranial cryptococcosis in immunocompromised patients: CT and MR findings in 29 cases. AJNR Am J Neuroradiol, 1991; 12, 283−9.
[70] Tu JS, Zhang SY, Liu HQ, et al. Cerebral infarction in HIV-negative patients with cryptococcal meningitis: its predictors and impact on outcomes. BMC Infect Dis, 2022; 22, 825. doi:  10.1186/s12879-022-07827-z
[71] Kovoor JME, Mahadevan A, Narayan JP, et al. Cryptococcal choroid plexitis as a mass lesion: MR imaging and histopathologic correlation. AJNR Am J Neuroradiol, 2002; 23, 273−6.
[72] Liu ZY, Wang GQ, Zhu LP, et al. Expert consensus on the diagnosis and treatment of cryptococcal meningitis. Chin J Intern Med, 2018; 57, 317−23. (In Chinese)
[73] Chinese Society of Neuroinfectious Diseases and Cerebrospinal Fluid Cytology. Chinese expert consensus on the diagnosis of non-human immunodeficiency virus related cryptococcal meningitis. Chin J Neurol, 2023; 56, 1093−102. (In Chinese)
[74] Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med, 2018; 378, 1004−17. doi:  10.1056/NEJMoa1710922
[75] Day JN, Chau TTH, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med, 2013; 368, 1291−1302. doi:  10.1056/NEJMoa1110404
[76] Takazono T, Hidaka Y, Morimoto S, et al. Comparison of liposomal amphotericin B alone and in combination with flucytosine in the treatment of non-HIV Cryptococcal meningitis: a nationwide observational study. Mycoses, 2022; 65, 897−902. doi:  10.1111/myc.13493
[77] Zhao HZ, Cao YH, Chen YQ, et al. Efficacy and safety of high-dose fluconazole in treatment of refractory cryptococcal meningitis. Chin J Infect Dis, 2015; 33, 146−9. (In Chinese)
[78] Ou XT, Geng CM, Xu B, et al. Analysis of 24 cases of cryptococcal meningitis treated with fluconazole. Chin J Infect Dis, 2009; 27, 357−9. (In Chinese)
[79] Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis, 2000; 30, 47−54. doi:  10.1086/313603
[80] Alanazi AH, Adil MS, Lin XR, et al. Elevated intracranial pressure in cryptococcal meningoencephalitis: examining old, new, and promising drug therapies. Pathogens, 2022; 11, 783. doi:  10.3390/pathogens11070783
[81] Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS, 2009; 23, 701−6. doi:  10.1097/QAD.0b013e32832605fe
[82] Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis, 2014; 59, 1607−14. doi:  10.1093/cid/ciu596
[83] Kagimu E, Engen N, Ssebambulidde K, et al. Therapeutic lumbar punctures in human immunodeficiency virus-associated cryptococcal meningitis: should opening pressure direct management?. Open Forum Infect Dis, 2022; 9, ofac416. doi:  10.1093/ofid/ofac416
[84] Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med, 2014; 370, 2487−98. doi:  10.1056/NEJMoa1312884
[85] Scriven JE, Rhein J, Hullsiek KH, et al. Early ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite randomized trial. J Infect Dis, 2015; 212, 769−78. doi:  10.1093/infdis/jiv067
[86] Ingle SM, Miro JM, May MT, et al. Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with human immunodeficiency virus in high-income countries: an international collaborative cohort study. Clin Infect Dis, 2023; 77, 64−73. doi:  10.1093/cid/ciad122
[87] Eshun-Wilson I, Okwen MP, Richardson M, et al. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev, 2018; 7, CD009012.
[88] Boulware DR, Jarvis JN. Timing of antiretroviral therapy in cryptococcal meningitis: what we can (and cannot) learn from observational data. Clin Infect Dis, 2023; 77, 74−6. doi:  10.1093/cid/ciad123
[89] Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS, 2013; 27, 2089−99. doi:  10.1097/QAD.0b013e3283614a8d
[90] Sun HY, Alexander BD, Huprikar S, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis, 2015; 60, 36−44. doi:  10.1093/cid/ciu711
[91] Deshayes S, Bouvier N, Chatelet V, et al. Severe cryptococcal-associated neurological immune reconstitution inflammatory syndrome in a renal transplant recipient treated with adalimumab. Transpl Infect Dis, 2016; 18, 461−5. doi:  10.1111/tid.12522
[92] AIDS-Associated Opportunistic Infections Research Group of the National Science and Technology Major Project of China during the 13th Five-Year Plan Period. Expert consensus on the diagnosis and treatment of cryptococcosis in AIDS patients. J Southwest Univ Nat Sci Ed, 2020; 42, 1−19. (In Chinese)
[93] Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med, 2010; 7, e1000384. doi:  10.1371/journal.pmed.1000384
[94] Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. S Afr J HIV Med, 2019; 20, 1030. doi:  10.4102/sajhivmed.v20i1.1030
[95] Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med, 2016; 374, 542−54. doi:  10.1056/NEJMoa1509024
[96] Macsween KF, Bicanic T, Brouwer AE, et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect, 2005; 51, e221−4. doi:  10.1016/j.jinf.2005.02.010
[97] Manosuthi W, Sungkanuparph S, Chottanapund S, et al. Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS, 2008; 19, 268−71. doi:  10.1258/ijsa.2007.007286
[98] Wang H, Ling C, Chen C, et al. Value of ventricular peritoneal shunt in treating patients with intracranial hypertension combined with cryptococcal meningitis. Chin J Neuromed, 2014; 13, 1269−73. (In Chinese)
[99] Gu L, Lin J, Li AM, et al. Clinical spectrum, immune status, and prognostic factors of cryptococcosis: insights from a large, multi-center, ambispective cohort study in southeastern China. Infect Dis Poverty, 2026; 15, 1. doi:  10.1186/s40249-025-01408-3
[100] Paccoud O, Desnos-Ollivier M, Persat F, et al. Features of cryptococcosis among 652 HIV-seronegative individuals in France: a cross-sectional observational study (2005-2020). Clin Microbiol Infect, 2024; 30, 937−44. doi:  10.1016/j.cmi.2024.03.031
[101] Baddley JW, Chen SCA, Huisingh C, et al. MSG07: an international cohort study comparing epidemiology and outcomes of patients with Cryptococcus neoformans or Cryptococcus gattii infections. Clin Infect Dis, 2021; 73, 1133−41. doi:  10.1093/cid/ciab268
[102] Howard-Jones AR, Sparks R, Pham D, et al. Pulmonary cryptococcosis. J Fungi, 2022; 8, 1156. doi:  10.3390/jof8111156
[103] Song KD, Lee KS, Chung MP, et al. Pulmonary cryptococcosis: imaging findings in 23 non-AIDS patients. Korean J Radiol, 2010; 11, 407−16. doi:  10.3348/kjr.2010.11.4.407
[104] Min JQ, Huang KL, Shi CM, et al. Pulmonary Cryptococcosis: comparison of Cryptococcal antigen detection and radiography in Immunocompetent and Immunocompromised patients. BMC Infect Dis, 2020; 20, 91. doi:  10.1186/s12879-020-4818-1
[105] Li ZT, Wang MD, Zeng PY, et al. Examination of a Chinese-made cryptococcal glucuronoxylomannan antigen test in serum and bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients. J Microbiol Immunol Infect, 2022; 55, 307−13. doi:  10.1016/j.jmii.2021.05.002
[106] Cheng KB, Wu ZH, Liang S, et al. Associations of serum cryptococcal antigen with different of clinical characteristics: a comprehensive analysis of 378 pulmonary cryptococcosis patients. Ann Palliat Med, 2021; 10, 681−93. doi:  10.21037/apm-21-127
[107] Li HR, Ma YM, Zeng ZH, et al. Follow-up of surgical or nonsurgical patients with pulmonary cryptococcosis: a real-world study. Infect Drug Resist, 2022; 15, 3669−81. doi:  10.2147/IDR.S352966
[108] Yan Y, Wu YX, Wang Q, et al. Lesion size as a prognostic factor in the antifungal treatment of pulmonary cryptococcosis: a retrospective study with chest CT pictorial review of 2-year follow up. BMC Infect Dis, 2023; 23, 153. doi:  10.1186/s12879-023-08131-0
[109] Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis, 2010; 50, 291−322. doi:  10.1086/649858
[110] Fujimura T, Nakamura S, Kiriyama R, et al. Pulmonary cryptococcosis treated with antifungal drugs after surgical resection: report of a case. Kyobu Geka, 2024; 77, 1135−40.
[111] Xie D, Chen XF, Jiang GN, et al. Clinical analysis of 81 cases of pulmonary cryptococcosis. Zhonghua Wai Ke Za Zhi, 2012; 50, 430−3. (In Chinese)
[112] Wei S, Su X, Pan YH, et al. Postoperative Antifungal Treatment of Pulmonary. Cryptococcosis in Non-HIV-Infected and Non-Transplant-Recipient Patients: A Report of 110 Cases and Literature Review. Open Forum Infect Dis, 2020; 7, ofaa004. doi:  10.1093/ofid/ofaa004
[113] Viola GM, Malek AE, Rosen LB, et al. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: an underappreciated association. Mycoses, 2021; 64, 576−82. doi:  10.1111/myc.13247
[114] Akintilo L, Femia A. Disseminated cryptococcosis. N Engl J Med, 2021; 385, 1699.
[115] Chen RC, Zhang YY, Zhou PC, et al. Cryptococcemia according to immune status: an analysis of 65 critical cases. Infect Dis Ther, 2021; 10, 363−71. doi:  10.1007/s40121-020-00375-6
[116] Johnson MM, Gajurel K. Disseminated cryptococcosis with cutaneous manifestation. Transpl Infect Dis, 2021; 23, e13412. doi:  10.1111/tid.13412
[117] Xu LJ, Zhang XY, Guo YZ, et al. Unique clinical features of cryptococcal meningitis among Chinese patients without predisposing diseases against patients with predisposing diseases. Med Mycol, 2019; 57, 944−53. doi:  10.1093/mmy/myy154
[118] Iyer KR, Revie NM, Fu C, et al. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat Rev Microbiol, 2021; 19, 454−66. doi:  10.1038/s41579-021-00511-0
[119] Noguchi H, Matsumoto T, Kimura U, et al. Cutaneous cryptococcosis. Med Mycol J, 2019; 60, 101−7. doi:  10.3314/mmj.19.008
[120] Wang YH, Lan J, Lin SH. Primary cutaneous cryptococcosis. JAMA Dermatol, 2024; 160, 995−6. doi:  10.1001/jamadermatol.2024.1899
[121] Srivastava GN, Tilak R, Yadav J, et al. Cutaneous Cryptococcus: marker for disseminated infection. BMJ Case Rep, 2015; 2015, bcr2015210898. doi:  10.1136/bcr-2015-210898
[122] Du L, Yang YL, Gu JL, et al. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients. Mycopathologia, 2015; 180, 19−25. doi:  10.1007/s11046-015-9880-7
[123] Yao ZR, Liao WQ, Chen RG. Management of cryptococcosis in non-HIV-related patients. Med Mycol, 2005; 43, 245−51. doi:  10.1080/13693780410001731628
[124] Qu H, Zhao Z, Yu J. Image Gallery: cutaneous presentation of disseminated cryptococcosis in a patient with undiagnosed HIV infection. Br J Dermatol, 2017; 177, e73. doi:  10.1111/bjd.15793
[125] Ioannidis N, Mavridis C, Anagnostakis G, et al. Disseminated cryptococcosis with prostate involvement in a patient with T-cell prolymphocytic leukemia and prostate cancer. Cureus, 2024; 16, e61555.
[126] Shah SI, Bui H, Velasco N, et al. Incidental finding of Cryptococcus on prostate biopsy for prostate adenocarcinoma following cardiac transplant: case report and review of the literature. Am J Case Rep, 2017; 18, 1171−80.
[127] Siddiqui TJ, Zamani T, Parada JP. Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient. J Infect, 2005; 51, e153−7. doi:  10.1016/j.jinf.2004.12.005
[128] Valero G, Graybill JR. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother, 1995; 39, 2588−90.